Surgical Treatment: Robotic Simple Prostatectomy

Carvalho, Paulo Afonso; Coelho, Rafael F.

doi:10.1007/978-3-319-64704-3_10

Cited by 1 publication

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cost was another controversial topic and should be taken into account. Cost-benefit analysis was a complex problem and affected by multiple factors such as hospital costs, complications, and reimbursement issues which vary significantly between countries and healthcare systems [58]. Sutherland et al [15] reported that RASP was expectedly expensive compared to OSP, adding an average of USD 2797 to the operating charges, which does not include the initial investment cost of the robotic system.…”

Section: Discussionmentioning

confidence: 99%

Robotic-Assisted Simple Prostatectomy: A Systematic Review

Kordan

Canda

Köseoğlu

et al. 2020

JCM

View full text Add to dashboard Cite

Contemporary minimally invasive surgical (MIS) treatment options of patients with male Lower Urinary Tract Symptoms (LUTS) in men with prostate glands >80 mL include Holmium Laser Enucleation Prostate (HoLEP), Thulium laser VapoEnucleation Prostate (ThuVEP), and Laparoscopic (LSP) or Robotic-Assisted Simple Prostatectomy (RASP). Implementing new laser technologies is costly, and the steep learning curve of these laser techniques limit their wide range use. This promoted the use of LSP and RASP in centers with readily established laparoscopy or robotic surgery programs. The aim of this study is to review case and comparative series of RASP. We systematically reviewed published data from 2008 to 2020 on RASP and have identified 26 non-comparative and 9 comparative case series. RASP has longer operation time but less time spent in hospital and less blood loss. The outcomes of improvements in symptom score, post-voiding residual urine (PVR), postoperative PSA decline, complications, and cost are similar when compared to open and laser enucleation techniques. These outcomes position RASP as a viable MIS treatment option for patients with male LUTS needing surgical treatment for enlarged prostates. Nevertheless, prospective, randomized controlled trials (RCTs) with multicenter and large sample size are needed to confirm the findings of this systematic review.

show abstract

Section: Discussionmentioning

confidence: 99%